A manufacturer in Viet Nam cannot hold an EU marketing authorisation in its own name. The holder has to be established in the EEA.
EU law says so directly. Directive 2001/83/EC grants a marketing authorisation only to an applicant established in the Union, and Regulation (EC) No 726/2004 says the same for the centralised procedure. The EEA agreement extends this to Iceland, Liechtenstein and Norway.
For a plant planning EU export, that makes the marketing authorisation holder (MAH) one of the first decisions on the roadmap, well before the dossier is written. The MAH carries legal responsibility for the product on the EU market: variations, pharmacovigilance, and the arrangement with the Qualified Person who certifies batches for release in the EU. A factory can pass an EU GMP inspection and still sell nothing if nobody in the EEA is willing and able to take that role.
The practical routes are an EEA partner who holds the authorisation and contracts the site, an EEA subsidiary, or acquiring an existing authorisation and transferring manufacture to the new site. Each one changes the timeline, the dossier and who controls the product.
Humiley's EU-GMP roadmap consulting covers QMS, CTD/eCTD dossier, technology transfer, MAH, QP and pharmacovigilance. The MAH question usually comes first.
Topics
Industries




